Association of Prior 5-Alpha-Reductase Inhibitor Exposure With Immune Checkpoint Inhibitor Benefit in Metastatic Renal Cell Carcinoma: Multicenter Cohort With Single-Cell Immune Profiling

    March 2026 in “ Journal of Clinical Oncology ”
    Bisheng Cheng, Peng Wu
    Studysummary In this study, pre-treatment with 5-α-reductase inhibitors (finasteride/dutasteride) in patients with metastatic renal cell carcinoma was associated with better immune checkpoint inhibitor effectiveness and improved progression-free and overall survival, without increasing severe side effects.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on doi.org →
    Discuss this study in the Community →